Dexrazoxane is a chelating agent that interferes with iron-mediated radicals thought to be responsible for anthracycline-induced cardiotoxicity.

Reduction of the incidence and severity of cardiomyopathy associated with doxorubicin therapy in women with metastatic breast cancer who have received a cumulative dose of 300 mg/m² and who could benefit from continued doxorubicin therapy.

Not bound to plasma proteins; 42% of the dose is excreted in the urine.